All Stories

  1. Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial

    Article • Diabetes Obesity and Metabolism, December 2024, Wiley

    James Mancuso

  2. Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

    Article • European Heart Journal, October 2023, Oxford University Press (OUP)

    James Mancuso

  3. Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts

    Article • Therapeutic Innovation & Regulatory Science, October 2023, Springer Science + Business Media

    James Mancuso

  4. IDF2022-0796 Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV

    Article • Diabetes Research and Clinical Practice, March 2023, Elsevier

    James Mancuso

  5. HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL

    Article • Journal of the American College of Cardiology, March 2023, Elsevier

    James Mancuso

  6. Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

    Article • Diabetes Obesity and Metabolism, February 2023, Wiley

    James Mancuso, Professor Deepak L Bhatt

  7. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial

    Article • Sleep Medicine, December 2022, Elsevier

    James Mancuso

  8. Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

    Article • European Heart Journal, October 2022, Oxford University Press (OUP)

    James Mancuso

  9. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

    Article • Circulation, August 2022, Wolters Kluwer Health

    James Mancuso

  10. 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV

    Article • Diabetes, June 2022, American Diabetes Association

    James Mancuso

  11. 859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV

    Article • Diabetes, June 2022, American Diabetes Association

    James Mancuso

  12. 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

    Article • Diabetes, June 2022, American Diabetes Association

    James Mancuso, Professor Deepak L Bhatt

  13. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

    Article • Sleep And Breathing, May 2022, Springer Science + Business Media

    James Mancuso

  14. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis fromVERTIS CV

    Article • Diabetes Obesity and Metabolism, March 2022, Wiley

    James Mancuso

  15. Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

    Article • European Heart Journal, October 2021, Oxford University Press (OUP)

    James Mancuso

  16. 783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV

    Article • Diabetes, June 2021, American Diabetes Association

    James Mancuso

  17. 786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV

    Article • Diabetes, June 2021, American Diabetes Association

    James Mancuso

  18. 796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV

    Article • Diabetes, June 2021, American Diabetes Association

    James Mancuso

  19. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease

    Article • Circulation, December 2020, Wolters Kluwer Health

    James Mancuso

  20. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2020, New England Journal of Medicine (NEJM/MMS)

    James Mancuso

  21. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

    Article • Current Medical Research and Opinion, May 2020, Taylor & Francis

    James Mancuso

  22. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

    Article • Current Medical Research and Opinion, May 2020, Taylor & Francis

    James Mancuso

  23. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

    Article • Diabetes Therapy, May 2020, Springer Science + Business Media

    James Mancuso

  24. 2353-PUB: Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)

    Article • Diabetes, June 2019, American Diabetes Association

    James Mancuso

  25. FP485EFFECTS OF ERTUGLIFLOZIN TREATMENT OVER 2 YEARS ON MEASURES OF RENAL FUNCTION

    Article • Nephrology Dialysis Transplantation, June 2019, Oxford University Press (OUP)

    James Mancuso

  26. 1197-P: Two-Year Effects of Ertugliflozin on Renal Function

    Article • Diabetes, June 2019, American Diabetes Association

    James Mancuso

  27. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

    Article • Current Medical Research and Opinion, February 2019, Taylor & Francis

    James Mancuso

  28. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

    Article • American Heart Journal, December 2018, Elsevier

    James Mancuso

  29. Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM)

    Article • Diabetes, July 2018, American Diabetes Association

    James Mancuso

  30. Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin

    Article • Diabetes, July 2018, American Diabetes Association

    James Mancuso

  31. A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin

    Article • Diabetes, July 2018, American Diabetes Association

    James Mancuso

  32. Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin

    Article • Diabetes, July 2018, American Diabetes Association

    James Mancuso

  33. Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin

    Article • Diabetes, July 2018, American Diabetes Association

    James Mancuso

  34. How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables

    Article • Therapeutic Innovation & Regulatory Science, June 2018, SAGE Publications

    James Mancuso

  35. DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)

    Article • Journal of the American College of Cardiology, March 2018, Elsevier

    James Mancuso

  36. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

    Article • Diabetes Therapy, December 2017, Springer Science + Business Media

    James Mancuso

  37. P4‐323: A comparison of crossover versus parallel‐arm clinical study designs in evaluating the psychomotor and cognitive deficits induced by scopolamine

    Article • Alzheimer s & Dementia, July 2012, Wiley

    James Mancuso

  38. Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men

    Article • Obesity, August 2010, Wiley

    James Mancuso

  39. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects

    Article • Clinical Pharmacology & Therapeutics, July 2009, Wiley

    James Mancuso

  40. Do Methodological Flaws Invalidate a Randomized Trial of Lifestyle Modification Programs in Obese Patients?

    Article • Annals of Internal Medicine, July 2009, American College of Physicians

    James Mancuso

  41. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism

    Article • Journal of Lipid Research, July 2009, Elsevier

    James Mancuso

  42. Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension

    Article • Hypertension, June 2009, Wolters Kluwer Health

    James Mancuso

  43. Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials

    Article • Drug Information Journal, July 2008, Springer Science + Business Media

    James Mancuso

  44. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism

    Article • Journal of Lipid Research, March 2008, Elsevier

    James Mancuso

  45. Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76

    Article • Diabetologia, October 2006, Springer Science + Business Media

    James Mancuso

  46. Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans

    Article • Arteriosclerosis Thrombosis and Vascular Biology, June 2006, Wolters Kluwer Health

    James Mancuso

  47. Mo-W1:1 Effects of cholesteryl ester transfer protein inhibition on lipoprotein metabolism in humans

    Article • Atherosclerosis Supplements, January 2006, Elsevier

    James Mancuso

  48. Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion

    Article • Arteriosclerosis Thrombosis and Vascular Biology, May 2005, Wolters Kluwer Health

    James Mancuso

  49. Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, April 2004, New England Journal of Medicine (NEJM/MMS)

    James Mancuso

  50. Age-Adjusted Exact Trend Tests in the Event of Rare Occurrences

    Article • Biometrics, June 2002, Wiley

    James Mancuso

  51. A Microsoft Fortran 77 Program for Contrasting Part Correlations and Related Statistics

    Article • Educational and Psychological Measurement, October 1995, SAGE Publications

    James Mancuso